Retrospective study investigating naloxone prescribing and cost in US Medicaid and Medicare patients.
BMJ Open
; 14(5): e078592, 2024 May 01.
Article
em En
| MEDLINE
| ID: mdl-38692729
ABSTRACT
BACKGROUND:
Opioid overdoses in the USA have increased to unprecedented levels. Administration of the opioid antagonist naloxone can prevent overdoses.OBJECTIVE:
This study was conducted to reveal the pharmacoepidemiologic patterns in naloxone prescribing to Medicaid patients from 2018 to 2021 as well as Medicare in 2019.DESIGN:
Observational pharmacoepidemiologic studySETTING:
US Medicare and Medicaid naloxone claims INTERVENTION The Medicaid State Drug Utilisation Data File was utilised to extract information on the number of prescriptions and the amount prescribed of naloxone at a national and state level. The Medicare Provider Utilisation and Payment was also utilised to analyse prescription data from 2019. OUTCOMEMEASURES:
States with naloxone prescription rates that were outliers of quartile analysis were noted.RESULTS:
The number of generic naloxone prescriptions per 100 000 Medicaid enrollees decreased by 5.3%, whereas brand naloxone prescriptions increased by 245.1% from 2018 to 2021. There was a 33.1-fold difference in prescriptions between the highest (New Mexico=1809.5) and lowest (South Dakota=54.6) states in 2019. Medicare saw a 30.4-fold difference in prescriptions between the highest (New Mexico) and lowest states (also South Dakota) after correcting per 100 000 enrollees.CONCLUSIONS:
This pronounced increase in the number of naloxone prescriptions to Medicaid patients from 2018 to 2021 indicates a national response to this widespread public health emergency. Further research into the origins of the pronounced state-level disparities is warranted.Palavras-chave
Texto completo:
1
Temas:
ECOS
/
Aspectos_gerais
/
Estado_mercado_regulacao
/
Financiamentos_gastos
Bases de dados:
MEDLINE
Assunto principal:
Medicare
/
Medicaid
/
Naloxona
/
Antagonistas de Entorpecentes
Limite:
Humans
/
Male
País/Região como assunto:
America do norte
Idioma:
En
Revista:
BMJ Open
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Estados Unidos